3Z closes $2 million funding for preclinical development of novel ADHD and Insomnia therapeutics identified by 3Z´s zebrafish drug discovery platform.
Reykjavik – 3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a $2 million funding round led by seasoned investors in pharmaceuticals and medical technology. The just closed funding will accelerate finalization of preclinical studies on 3Z´s lead therapeutic candidates in ADHD and insomnia. Using its unique zebrafish screening platform, 3Z has identified both novel and repurposed therapeutics for these indications; the platform allows for cost-effective high-volume screens in vivo.Currently, the lead therapeutics are being re-assayed in mammalian models,